24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
U.S. Coronavirus Cases Near 3 Million as Hospitals in Sun Belt Fill Up With PatientsAHA News: Months After Infection, Many COVID-19 Patients Can't Shake IllnessCoronavirus Ups Anxiety, Depression in the LGBTQ CommunityMajor Medical Groups Urge Americans to Wear Face MasksBlack Patients Fare Worse After AngioplastyHow Immune System Fights COVID-19 May Be Key to Vaccine SuccessWill the COVID-19 Pandemic Leave a Mental Health Crisis in Its Wake?New U.S. Coronavirus Cases Hit Another HighMultiple Surgeries for Cleft Lip, Palate Won't Cause Major Psychological DamageHIV May Not Worsen COVID-19 OutlookU.S. Coronavirus Hospitalizations Spiking in South, WestAHA News: To Everything There Is a Season, Including Heart DiseaseAsthma, Allergies Plus Pandemic May Pose 4th of July ChallengesStroke Appears 8 Times More Likely With COVID Than With FluCOVID-19 Death Risk Twice as High in New York City as Some CountriesFireworks Are Bad News for Your LungsScientists Find Source of COVID ClotsNew U.S. Coronavirus Cases Top 50,000 as More States Slow Reopening PlansNumbers of Non-COVID-19 Deaths Up During PandemicNo Good Evidence on Accuracy of Coronavirus Antibody Tests: StudyAHA News: COVID-19 Pandemic Brings New Concerns About Excessive DrinkingMuscle Relaxants for Back Pain Are Soaring: Are They Safe?Trauma of Racism Fuels High Blood Pressure Among Black Americans: StudyCOVID-19 Blood Test Might Predict Who Will Need a VentilatorWhat's the Best DIY Face Mask Against COVID-19?Deep Brain Stimulation May Slow Parkinson's, Study FindsU.S. Could See 100,000 New Cases of COVID-19 Each Day, Fauci SaysGlobally, COVID-19 Cases May Stretch Far Beyond Official Numbers: StudyFBI: Beware of Scammers Selling Fake COVID-19 Antibody TestsAHA News: Sadness and Isolation of Pandemic Can Make Coping With Grief HarderVaping-Related Lung Injuries Still Happening -- And May Look Like COVID-19Most With Coronavirus Not Sure How They Caught It: CDCDon't Get Sick While Swimming This SummerAmid Pandemic, Too Many Americans Are Hesitating to Call 911Mask Up! Don't Let Down Your Guard Against COVID-19Wildfire Smoke Causes Rapid Damage to Your Health: StudyCOVID Drug Remdesivir Could Cost Up to $3,120 Per Patient, Maker SaysIntestinal Illness Spurs Recall of Bagged Salads Sold at Walmart, AldiCOVID Threatens the 3 out of 4 Americans Who Can't Work From HomeHispanic Americans Being Hit Hard By COVID-19Global Coronavirus Cases Pass 10 Million as U.S. Struggles With Surge in InfectionsStarted Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: StudyIs 'Pooled' Coronavirus Testing the Next Step for America?U.S. Coronavirus Task Force Warns of Rising Case Numbers, Especially Among YoungWho's at Highest Risk From COVID-19? CDC Updates Its ListStroke, Confusion: COVID-19 Often Impacts the Brain, Study ShowsPromising Results Mean Coronavirus Vaccine Trial Could Start by AugustWhen Can Sports Fans Safely Fill Stadiums Again?Coronavirus Baby Boom? Survey Says Maybe NotCOVID-19 Typically Mild for Babies: Study
Questions and AnswersLinks
Related Topics

Diabetes

Inhaled Remdesivir May Allow COVID-19 Patients to Be Treated at Home

HealthDay News
by -- Robert Preidt
Updated: Jun 22nd 2020

new article illustration

MONDAY, June 22, 2020 (HealthDay News) -- An inhaled version of the antiviral drug remdesivir will soon be tested outside a hospital setting, Gilead Sciences announced Monday.

Remdesivir, which is made by Gilead, is now being used to treat COVID-19 patients worldwide. Currently, the drug has to be given intravenously through daily infusions in the hospital.

"An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of disease," Gilead chairman and CEO Daniel O'Day said in a company news release.

"That could have significant implications in helping to stem the tide of the pandemic," he added.

Screening will start this week for healthy volunteers to take part in Phase 1 trials of inhaled remdesivir and the trials should start in August, the company said.

"As part of our next wave of clinical development, we will study remdesivir in treating earlier in the disease, in combination with other therapies and in additional patient groups," O'Day explained.

Other clinical trials of intravenous remdesivir have assessed its safety and efficacy in hospitalized patients. A U.S. National Institute of Allergy and Infectious Diseases (NIAID) study found that the drug shortened recovery time by an average of four days, and a study of moderately ill patients (hospitalized but not requiring oxygen) found that those who received five days of treatment with remdesivir had better outcomes than those who received standard care.

The NIAID data also showed that remdesivir was most effective in patients who did not yet require medical ventilation, supporting further study of the drug in patients earlier in the disease, according to O'Day.

The inhaled version is one way of assessing the use of remdesivir in the earlier stages of COVID-19.

"We will also conduct trials using intravenous infusions in outpatient settings such as infusion centers and nursing homes. For patients who are at high risk of disease progression, it could be particularly beneficial to start treatment outside the hospital," O'Day said.

"Our hope is that earlier intervention could help patients avoid hospitalization altogether," O'Day said. "Based on our knowledge of the disease so far, it seems that in the earlier stages of COVID-19, the virus itself is the primary driver of illness."

He noted that in the later stages of the disease, "the body's inflammatory response may cause some of the most life-threatening aspects of the disease," he said. "It is important, therefore, to have tools that can work together to fight both aspects of the disease: an antiviral to target the virus itself and another therapy to tackle the inflammatory response."

In the coming months, results are expected from trials of remdesivir with two immune system modulators, the JAK inhibitor baricitinib and the IL-6 receptor antagonist tocilizumab.

"Last week's news on dexamethasone appears to further support the study of complementary approaches for treating COVID-19. Dexamethasone is a steroid that potentially reduces the body's inflammatory response to the virus. In addition to extending our focus to earlier treatment and combinations, our next wave of studies of remdesivir will include vulnerable patient populations," O'Day said.

Last week, Gilead announced a clinical trial for children that will include about 50 newborns to teens hospitalized with COVID-19, and the company is also collaborating with a partner on a study in pregnant women.

O'Day said the company is working on ensuring sufficient supplies of remdesivir.

"We now expect to have more than 2 million remdesivir treatment courses manufactured by the end of the year and many millions more by 2021. Our scientists will stay focused on optimizing the manufacturing process, and we will continue to collaborate globally to ensure sufficient worldwide supply. We donated our entire existing supplies of remdesivir through June," he said.

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19.